Literature DB >> 24497611

B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21.

Magdalena Hagn1, Sue E Blackwell2, Thamara Beyer3, Verena Ebel4, Dorit Fabricius5, Stefanie Lindner3, Stefan Stilgenbauer6, Thomas Simmet4, Constantine Tam1, Paul Neeson1, Joseph A Trapani1, Hubert Schrezenmeier3, George J Weiner2, Bernd Jahrsdörfer7.   

Abstract

CpG oligodeoxynucleotides (CpG) and IL-21 are two promising agents for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). Recently, we reported that the combination of CpG and IL-21 (CpG/IL-21) can induce granzyme B (GrB)-dependent apoptosis in B-CLL cells. Here, we demonstrate that treatment of B-CLL cells with CpG and IL-21 results in the development of antigen-presenting cell (APC)-like cells with cytotoxic features. These properties eventually give rise to B-CLL cell apoptosis, independently of their cytogenetic phenotype, whereas normal B-cell survival is not negatively affected by CpG/IL-21. APC- and CTL-typical molecules found to be up-regulated in CpG/IL-21-stimulated B-CLL cells include GrB, perforin, T-bet, monokine-induced by IFN-γ and IFN-γ-inducible protein 10 (IP-10), as well as molecules important for cell adhesion, antigen cross-presentation and costimulation. Also induced are molecules involved in GrB induction, trafficking and processing, whereas the GrB inhibitor Serpin B9 [formerly proteinase inhibitor-9 (PI-9)] is down-modulated by CpG/IL-21. In conclusion, CpG/IL-21-stimulated B-CLL cells acquire features that are reminiscent of killer dendritic cells, and which result in enhanced immunogenicity, cytotoxicity and apoptosis. Our results provide novel insights into the aberrant immune state of B-CLL cells and may establish a basis for the development of an innovative cellular vaccination approach in B-CLL. © The Japanese Society for Immunology. 2014. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  cross-presentation; cytotoxic B cells; immunogenization; leukemia vaccine; toll-like receptor agonist

Mesh:

Substances:

Year:  2014        PMID: 24497611      PMCID: PMC4133571          DOI: 10.1093/intimm/dxu001

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  48 in total

1.  Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity.

Authors:  L Casciola-Rosen; F Andrade; D Ulanet; W B Wong; A Rosen
Journal:  J Exp Med       Date:  1999-09-20       Impact factor: 14.307

2.  CD86 and CD80 differentially modulate the suppressive function of human regulatory T cells.

Authors:  Yong Zheng; Claire N Manzotti; Michael Liu; Fiona Burke; Karen I Mead; David M Sansom
Journal:  J Immunol       Date:  2004-03-01       Impact factor: 5.422

3.  IFN-α enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing.

Authors:  Francesca Spadaro; Caterina Lapenta; Simona Donati; Laura Abalsamo; Vincenzo Barnaba; Filippo Belardelli; Stefano M Santini; Maria Ferrantini
Journal:  Blood       Date:  2011-12-19       Impact factor: 22.113

4.  Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells.

Authors:  Bernd Jahrsdörfer; James E Wooldridge; Sue E Blackwell; Christiana M Taylor; Thomas S Griffith; Brian K Link; George J Weiner
Journal:  J Leukoc Biol       Date:  2004-12-06       Impact factor: 4.962

5.  IL-21 as new therapy for CLL?

Authors:  Jean-Pierre Kolb
Journal:  Blood       Date:  2008-05-01       Impact factor: 22.113

6.  Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I.

Authors:  Tiziana Di Pucchio; Bithi Chatterjee; Anna Smed-Sörensen; Sandra Clayton; Adam Palazzo; Monica Montes; Yaming Xue; Ira Mellman; Jacques Banchereau; John E Connolly
Journal:  Nat Immunol       Date:  2008-03-30       Impact factor: 25.606

7.  CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia.

Authors:  W G Wierda; M J Cantwell; S J Woods; L Z Rassenti; C E Prussak; T J Kipps
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

8.  Human B cells secrete granzyme B when recognizing viral antigens in the context of the acute phase cytokine IL-21.

Authors:  Magdalena Hagn; Elisabeth Schwesinger; Verena Ebel; Kai Sontheimer; Julia Maier; Thamara Beyer; Tatiana Syrovets; Yves Laumonnier; Dorit Fabricius; Thomas Simmet; Bernd Jahrsdörfer
Journal:  J Immunol       Date:  2009-07-10       Impact factor: 5.422

9.  B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides.

Authors:  Bernd Jahrsdorfer; Lars Mühlenhoff; Sue E Blackwell; Moritz Wagner; Hendrik Poeck; Evelyn Hartmann; Ralf Jox; Thomas Giese; Bertold Emmerich; Stefan Endres; George J Weiner; Gunther Hartmann
Journal:  Clin Cancer Res       Date:  2005-02-15       Impact factor: 12.531

Review 10.  From normal to clonal B cells: Chronic lymphocytic leukemia (CLL) at the crossroad between neoplasia and autoimmunity.

Authors:  Paolo Ghia; Cristina Scielzo; Michela Frenquelli; Marta Muzio; Federico Caligaris-Cappio
Journal:  Autoimmun Rev       Date:  2007-03-22       Impact factor: 9.754

View more
  6 in total

1.  New Method for the Expansion of Highly Purified Human Regulatory Granzyme B-Expressing B Cells.

Authors:  Mélanie Chesneau; Hoa Le Mai; Sophie Brouard
Journal:  Methods Mol Biol       Date:  2021

Review 2.  Regulatory B lymphocyte functions should be considered in chronic lymphocytic leukemia.

Authors:  Audrey Mohr; Yves Renaudineau; Cristina Bagacean; Jacques-Olivier Pers; Christophe Jamin; Anne Bordron
Journal:  Oncoimmunology       Date:  2016-03-16       Impact factor: 8.110

Review 3.  IL-21: a pleiotropic cytokine with potential applications in oncology.

Authors:  Michela Croce; Valentina Rigo; Silvano Ferrini
Journal:  J Immunol Res       Date:  2015-04-15       Impact factor: 4.818

4.  CpG oligodeoxynucleotide CpG-685 upregulates functional interleukin-21 receptor on chronic lymphocytic leukemia B cells through an NF-κB mediated pathway.

Authors:  Rebekah L Browning; Xiaokui Mo; Natarajan Muthusamy; John C Byrd
Journal:  Oncotarget       Date:  2015-06-30

5.  GIFT4 fusokine converts leukemic B cells into immune helper cells.

Authors:  Jiusheng Deng; Andrea Pennati; Jonathon B Cohen; Yuanqiang Wu; Spencer Ng; Jian Hui Wu; Christopher R Flowers; Jacques Galipeau
Journal:  J Transl Med       Date:  2016-04-27       Impact factor: 5.531

Review 6.  The Biological Effects of IL-21 Signaling on B-Cell-Mediated Responses in Organ Transplantation.

Authors:  Yongkang Wu; Nicole M van Besouw; Yunying Shi; Martin J Hoogduijn; Lanlan Wang; Carla C Baan
Journal:  Front Immunol       Date:  2016-08-23       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.